Southern Missouri Bancorp (NASDAQ:SMBC) reported quarterly earnings of $1.53 per share. This is a 101.32 percent increase over earnings of $0.76 per share from the same period last year.
Dyne Therapeutics Presents Preclinical Data From Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress October 11-15
- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping -
- First Presentation of In Vitro Data for FORCE™ Platform
